GAMMA Investing LLC Purchases New Shares in ABIVAX Société Anonyme (NASDAQ:ABVX)

GAMMA Investing LLC acquired a new position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in the 4th quarter, Holdings Channel.com reports. The fund acquired 3,976 shares of the company’s stock, valued at approximately $29,000.

A number of other hedge funds have also bought and sold shares of ABVX. Point72 Asset Management L.P. lifted its holdings in shares of ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after buying an additional 119,300 shares during the period. Walleye Capital LLC increased its stake in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after buying an additional 80,807 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after acquiring an additional 5,900 shares in the last quarter. Finally, abrdn plc lifted its stake in ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after acquiring an additional 198,225 shares during the period. Institutional investors own 47.91% of the company’s stock.

Wall Street Analysts Forecast Growth

ABVX has been the topic of a number of analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, ABIVAX Société Anonyme currently has a consensus rating of “Buy” and an average price target of $38.67.

ABIVAX Société Anonyme Trading Down 5.4 %

Shares of ABVX opened at $6.15 on Wednesday. The firm has a 50-day simple moving average of $8.22 and a two-hundred day simple moving average of $10.33. ABIVAX Société Anonyme has a 1-year low of $5.54 and a 1-year high of $17.02.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.